Form 8-K - Current report:
SEC Accession No. 0001711279-25-000078
Filing Date
2025-08-04
Accepted
2025-08-04 07:09:44
Documents
13
Period of Report
2025-08-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K krys-20250804.htm   iXBRL 8-K 33626
2 EX-99.1 a2q25exhibit991pr.htm EX-99.1 124212
  Complete submission text file 0001711279-25-000078.txt   281164

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT krys-20250804.xsd EX-101.SCH 1791
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT krys-20250804_lab.xml EX-101.LAB 20073
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT krys-20250804_pre.xml EX-101.PRE 11516
15 EXTRACTED XBRL INSTANCE DOCUMENT krys-20250804_htm.xml XML 2634
Mailing Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203
Business Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203 (412) 586-5830
Krystal Biotech, Inc. (Filer) CIK: 0001711279 (see all company filings)

EIN.: 821080209 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38210 | Film No.: 251177970
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)